Freddie C. Hamdy

Generating author description...

All published works

Action	Title	Year	Authors
+	Specificity of a polygenic score for aggressive prostate cancer	2025	Anna Dornisch George Xu Roshan Karunamuni Charles A. Brunette Morgan Danowski Craig C. Teerlink J. Michael Gaziano Isla P. Garraway Richard Hauger Adam S. Kibel
+	From a genomic risk model to clinical trial implementation in a learning health system: the ProGRESS Study	2024	Jason L. Vassy Anna Dornisch Roshan Karunamuni Michael Gatzen Christopher Kachulis Niall J. Lennon Charles A. Brunette Morgan E. Danowski Richard L. Hauger Isla P. Garraway
+ PDF Chat	Endemic statistical paradoxes in epidemiologic studies distort knowledge on prostate cancer: mitigation and caution of fallacies in prostate cancer causal epidemiological studies	2023	Olivier Cussenot Gaëlle Fromont Géraldine Cancel‐Tassin Freddie C. Hamdy Richard M. Martin
+	Beyond attention: deriving biologically interpretable insights from weakly-supervised multiple-instance learning models	2023	Willem Bonnaffé CRUK ICGC Prostate Group Freddie C. Hamdy Yang Hu Ian G. Mills Jens Rittscher Clare Verrill Dan J. Woodcock
+ PDF Chat	Additional SNPs improve the performance of a polygenic hazard score for prostate cancer	2020	Roshan Karunamuni Minh‐Phuong Huynh‐Le Chun Chieh Fan Wesley K. Thompson Rosalind A. Eeles Zsofia Kote‐Jarai Kenneth Muir Artitaya Lophatananon Johanna Schleutker Nora Pashayan
+ PDF Chat	Polygenic Hazard Score for Prostate Cancer Risk Stratification: Validation in Additional Longitudinal Cohorts	2019	K.E. Tye Minh‐Phuong Huynh‐Le Chun Fan Sonja I. Berndt Freddie C. Hamdy Ian G. Mills Ole A. Andreassen Anders M. Dale Tyler M. Seibert
+ PDF Chat	Factors associated with trial recruitment, preferences, and treatments received were elucidated in a comprehensive cohort study	2019	Jenny Donovan Brent C. Opmeer Grace Young Nicola Mills Richard M. Martin J. Athene Lane Chris Metcalfe T. J. Peters Michael Davis Emma L. Turner
+ PDF Chat	A genetic hazard score to personalize prostate cancer screening, applied to population data	2019	Minh‐Phuong Huynh‐Le Chun Fan Roshan Karunamuni Eleanor Walsh Emma L. Turner J. Athene Lane Richard M. Martin David E. Neal Jenny Donovan Freddie C. Hamdy
+ PDF Chat	Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT	2018	Freddie C. Hamdy Daisy Elliott Steffi le Conte Lucy Davies Richéal Burns Claire Thomson Richard Gray Jane Wolstenholme Jenny Donovan Ray Fitzpatrick
+ PDF Chat	Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis	2018	Andrew J. Vickers Emily Vertosick Daniel D. Sjoberg Freddie C. Hamdy David E. Neal Anders Bjartell Jonas Hugosson Jenny Donovan Arnauld Villers Stephen Zappala
+ PDF Chat	A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial	2017	Jenny Donovan Grace Young Eleanor Walsh Chris Metcalfe J. Athene Lane Richard M. Martin Marta Tazewell Michael Davis T. J. Peters Emma L. Turner
+	Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer	2017	Freddie C. Hamdy Jenny Donovan
+ PDF Chat	10-Year Outcomes in Localized Prostate Cancer	2017	Freddie C. Hamdy Jenny Donovan David E. Neal
+	Statistical Analysis Plan: Prostate Testing for Cancer and Treatment (ProtecT) Study	2015	Chris Metcalfe T. J. Peters Freddie C. Hamdy
+	Description of statistical methods used to model repeated measures of prostate-specific antigen	2015	Andrew J. Simpkin Leila Rooshenas Julia Wade Jenny Donovan J. Athene Lane Richard M. Martin Chris Metcalfe Peter C. Albertsen Freddie C. Hamdy Lars Holmberg
+	Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial - Lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer) Data collection, quality, and reporting	2015	N J Williams Edward M. Hill Siaw Yein Ng Richard M. Martin Chris Metcalfe J L Donovan Simon Evans Laura Hughes Charlotte Davies Freddie C. Hamdy
+ PDF Chat	Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis	2015	Nora Pashayan Stephen W. Duffy David E. Neal Freddie C. Hamdy Jenny Donovan Richard M. Martin Patricia Harrington Sara Benlloch Ali Amin Al Olama Mitul Shah
+	Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis	2014	Nora Pashayan S W Duffy David E. Neal Freddie C. Hamdy J Donovan Richard M. Martin Patricia Harrington Sara Benlloch Ali Amin Al Olama Mitul Shah
+ PDF Chat	Misclassification of outcome in case–control studies: Methods for sensitivity analysis	2014	Rebecca Gilbert Richard M. Martin Jenny Donovan J. Athene Lane Freddie C. Hamdy David E. Neal Chris Metcalfe
+ PDF Chat	Evaluation of source data verification in a multicentre cancer trial (PROTECT)	2013	J. Athene Lane Michael Davis Liz Down Rhiannon Macefield David E. Neal Freddie C. Hamdy Jenny Donovan Hilary Taylor
+	Longitudinal prostate-specific antigen reference ranges: Choosing the underlying model of age-related changes	2013	Andrew J. Simpkin Chris Metcalfe Richard M. Martin J. Athene Lane Jenny Donovan Freddie C. Hamdy David E. Neal Kate Tilling
+ PDF Chat	Evaluating the Prostate Cancer Prevention Trial High Grade prostate cancer risk calculator in 10 international biopsy cohorts: results from the prostate biopsy collaborative group	2012	Donna P. Ankerst Andreas Boeck Stephen J. Freedland J. Stephen Jones Angel M. Cronin Monique J. Roobol Jonas Hugosson Michael W. Kattan Eric A. Klein Freddie C. Hamdy
+ PDF Chat	Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group	2011	Donna P. Ankerst Andreas Boeck Stephen J. Freedland Ian M. Thompson Angel M. Cronin Monique J. Roobol Jonas Hugosson J. Stephen Jones Michael W. Kattan Eric A. Klein
+ PDF Chat	Understanding factors influencing questionnaire response rates to maximise retention in a long term complex intervention trial	2011	J. Athene Lane Liz Down Julia Wade David E. Neal Freddie C. Hamdy Jenny Donovan
+	A Peer Review Intervention for Monitoring and Evaluating sites (PRIME) that improved randomized controlled trial conduct and performance	2011	J. Athene Lane Julia Wade Liz Down Susan Bonnington Peter Holding Teresa Lennon Amanda Jones C. Elizabeth Salter David E. Neal Freddie C. Hamdy
+ PDF Chat	043 Adjusting misclassification of outcome in case-control studies	2010	Rebecca Gilbert Richard M. Martin J. Athene Lane David E. Neal Freddie C. Hamdy J L Donovan Chris Metcalfe
+ PDF Chat	The Relationship between Prostate-Specific Antigen and Prostate Cancer Risk: The Prostate Biopsy Collaborative Group	2010	Andrew J. Vickers Angel M. Cronin Monique J. Roobol Jonas Hugosson J. Stephen Jones Michael W. Kattan Eric A. Klein Freddie C. Hamdy David E. Neal Jenny Donovan
+ PDF Chat	Current strategies for monitoring men with localised prostate cancer lack a strong evidence base: observational longitudinal study	2009	Chris Metcalfe Kate Tilling Mark Davis J. Athene Lane Richard M. Martin Howard Kynaston Philip Powell David E. Neal Freddie C. Hamdy J L Donovan
+	Prostate cancer: a systems approach overview	2008	Simon S. Cross Freddie C. Hamdy J R Goepel Robert F. Harrison
+	Application of Artificial Intelligence to the Management of Urological Cancer	2007	Maysam Abbod James W.F. Catto D.A. Linkens Freddie C. Hamdy
+ PDF Chat	Continuing Controversy Over Monitoring Men With Localized Prostate Cancer: A Systematic Review of Programs in the Prostate Specific Antigen Era	2006	Richard M. Martin David Gunnell Freddie C. Hamdy David E. Neal J. Athene Lane Jenny Donovan
+	A comparison of socio-demographic and psychological factors between patients consenting to randomisation and those selecting treatment (the ProtecT study)	2006	Nicola Mills Chris Metcalfe Carine Ronsmans Michael Davis J. Athene Lane Jonathan A C Sterne T. J. Peters Freddie C. Hamdy David E. Neal Jenny Donovan
+ PDF Chat	Prostate Testing for Cancer and Treatment (ProtecT) feasibility study	2003	Jenny Donovan Freddie C. Hamdy David E. Neal T. J. Peters Samuel J. Oliver Lucy Brindle David Jewell Philip Powell David Gillatt Daniel Dedman
+	Statistical and soft feature evaluation indices for prostate cancer prognostic factor assessments	2001	Hüseyin Şeker Michael Odetayo Dobrila Petrov́ić R.N.G. Naguib Freddie C. Hamdy
+	Comparison between artificial neural networks and urologists' assessment of outcome in bladder cancer - Part I: Progression and recurrence in Ta/T1 tumours	1999	R.N.G. Naguib K N Qureshi Freddie C. Hamdy David E. Neal J. Kilian Mellon
+	A general regression neural network analysis of prognostic markers in prostate cancer	1998	R.N.G. Naguib Freddie C. Hamdy

Common Coauthors

Coauthor	Papers Together
David E. Neal	26
Jenny Donovan	23
J. Athene Lane	16
Richard M. Martin	15
Chris Metcalfe	10
Emma L. Turner	6
Ian G. Mills	5
Ole A. Andreassen	5
Anders M. Dale	5
Tyler M. Seibert	5
Rosalind A. Eeles	5
T. J. Peters	5
Arnauld Villers	4
Nicola Mills	4
Monique J. Roobol	4
Michael Davis	4
Adam S. Kibel	4
Hans Lilja	4
James W.F. Catto	4
Andrew J. Vickers	4
Nora Pashayan	4
Eleanor Walsh	4
Jonas Hugosson	4
Ali Amin Al Olama	3
Julia Wade	3
Dipen J. Parekh	3
Zsofia Kote‐Jarai	3
Douglas F. Easton	3
Peter Holding	3
Jyotsna Batra	3
Fritz H. Schröder	3
Liz Down	3
Jong Y. Park	3
R.N.G. Naguib	3
David Gillatt	3
Ruth C. Travis	3
Johanna Schleutker	3
Derek J. Rosario	3
Fredrik Wiklund	3
Minh‐Phuong Huynh‐Le	3
Eric A. Klein	3
Daniel M. Moreira	3
Kate Tilling	3
Helmut Klocker	3
Olivier Cussenot	3
Michael W. Kattan	3
Donna P. Ankerst	3
Howard Kynaston	3
A. Benchikh	3
Wolfgang Horninger	3

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+ PDF Chat	Prostate Testing for Cancer and Treatment (ProtecT) feasibility study	2003	Jenny Donovan Freddie C. Hamdy David E. Neal T. J. Peters Samuel J. Oliver Lucy Brindle David Jewell Philip Powell David Gillatt Daniel Dedman	4
+ PDF Chat	The Relationship between Prostate-Specific Antigen and Prostate Cancer Risk: The Prostate Biopsy Collaborative Group	2010	Andrew J. Vickers Angel M. Cronin Monique J. Roobol Jonas Hugosson J. Stephen Jones Michael W. Kattan Eric A. Klein Freddie C. Hamdy David E. Neal Jenny Donovan	2
+ PDF Chat	Reducing Unnecessary Biopsy During Prostate Cancer Screening Using a Four-Kallikrein Panel: An Independent Replication	2010	Andrew J. Vickers Angel M. Cronin Monique J. Roobol Caroline Savage Mari Peltola Kim Pettersson Peter T. Scardino Fritz H. Schröder Hans Lilja	2
+	Multiple imputation of discrete and continuous data by fully conditional specification	2007	Stef van Buuren	2
+	Computing the Cox model for case cohort designs.	1999	Terry M. Therneau Hongzhe Li	2
+	Performance of Prostate Cancer Prevention Trial Risk Calculator in a Contemporary Cohort Screened for Prostate Cancer and Diagnosed by Extended Prostate Biopsy	2009	Carvell T. Nguyen Changhong Yu Ayman Moussa Michael W. Kattan J. Stephen Jones	2
+	THE LASSO METHOD FOR VARIABLE SELECTION IN THE COX MODEL	1997	Robert Tibshirani	2
+ PDF Chat	Decision Curve Analysis: A Novel Method for Evaluating Prediction Models	2006	Andrew J. Vickers Elena B. Elkin	2
+ PDF Chat	A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results	2015	Tessa Kennedy‐Martin Sarah L. Hulin-Curtis Douglas E. Faries Susan Robinson Joseph A. Johnston	2
+	Variations in PSA doubling time in patients with prostate cancer on “watchful waiting”: Value of short-term PSADT determinations	2004	Phillip Ross Salaheddin M. Mahmud Andrew J. Stephenson Luís Souhami Simon Tanguay Armen Aprikian	2
+	Regression Shrinkage and Selection Via the Lasso	1996	Robert Tibshirani	2
+	Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach	1988	Elizabeth R. DeLong David M. DeLong Daniel L. Clarke‐Pearson	2
+	1873: External Validation of the Prostate Cancer Prevention Trial Risk Calculator in a Screened Population	2007	Dipen J. Parekh Amanda Beth Reed Donna P. Ankerst Betsy Higgins Javier Hernández Edith Canby‐Hagino Timothy C. Brand Dean A. Troyer Robin J. Leach Ian M. Thompson	2
+	Evaluation of artificial neural networks for the prediction of pathologic stage in prostate carcinoma	2001	Misop Han Peter B. Snow Jeffrey M. Brandt Alan W. Partin	1
+	Comparison of artificial neural networks with other statistical approaches	2001	Daniel J. Sargent	1
+ PDF Chat	Statistical Learning from a Regression Perspective	2016	Richard A. Berk	1
+	Testing the evolution process of prostate‐specific antigen in early stage prostate cancer: what is the proper underlying model?	2011	Eliezer Z. Prisman Amiram Gafni Antonio Finelli	1
+ PDF Chat	Applied logistic regression	1990	David W. Hosmer Stanley Lemeshow	1
+	Modeling Survival Data: Extending the Cox Model	2000	Terry M. Therneau Patricia M. Grambsch	1
+ PDF Chat	The role of volume‐weighted mean nuclear volume in predicting tumour biology and clinical behaviour in patients with prostate cancer undergoing watchful waiting	2001	Yoichi Arai Shin Egawa Sadahito Kuwao K. Ogura Shiro Baba	1
+ PDF Chat	Sensitivity analysis for misclassification in logistic regression via likelihood methods and predictive value weighting	2010	Robert H. Lyles Ji Lin	1
+ PDF Chat	Testing for familial aggregation of functional traits	2009	Yixin Fang Yuanjia Wang	1
+	Novel Artificial Neural Network for Early Detection of Prostate Cancer	2002	Bob Djavan Mesut Remzi Alexandre R. Zlotta Christian Seitz Peter B. Snow Michael Marberger	1
+ PDF Chat	Management and Conduct of Randomized Controlled Trials	2002	Genell L. Knatterud	1
+	Predictors of Treatment After Initial Surveillance in Men With Prostate Cancer: Results From CaPSURE	2003	Maxwell V. Meng Eric P. Elkin Susan R. Harlan S. Mehta Deborah P. Lubeck Peter R. Carroll	1
+	Active Surveillance with Selective Delayed Intervention: A Biologically Nuanced Approach to Favorable-Risk Prostate Cancer	2003	Laurence Klotz	1
+	Watchful Waiting or Watchful Progression? Prostate Specific Antigen Doubling Times and Clinical Behavior in Patients With Early Untreated Prostate Carcinoma	1998	Duncan B. McLaren Michael McKenzie Gillian Duncan Tom Pickles	1
+	A neural network predicts progression for men with Gleason score 3+4 versus 4+3 tumors after radical prostatectomy	2000	Misop Han Peter B. Snow Jonathan I. Epstein Theresa Y. Chan Kerrie A. Jones Patrick C. Walsh Alan W Partin	1
+ PDF Chat	Logistic Regression When the Outcome Is Measured with Uncertainty	1997	Laurence S. Magder James P. Hughes	1
+	Can Prostate Specific Antigen Derivatives and Pathological Parameters Predict Significant Change in Expectant Management Criteria for Prostate Cancer?	2003	Masood A. Khan H. Ballentine Carter Jonathan I. Epstein Michael Craig Miller Patricia Landis Patrick Walsh Alan W. Partin Robert W. Veltri	1
+ PDF Chat	Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group	2011	Donna P. Ankerst Andreas Boeck Stephen J. Freedland Ian M. Thompson Angel M. Cronin Monique J. Roobol Jonas Hugosson J. Stephen Jones Michael W. Kattan Eric A. Klein	1
+	Prostate-Specific Antigen Kinetics in Clinical Decision-Making During Active Surveillance for Early Prostate Cancer—A Review	2008	Roderick C.N. van den Bergh Stijn Roemeling Monique J. Roobol Tineke Wolters Fritz H. Schröder Chris H. Bangma	1
+	Watchful Waiting and Factors Predictive of Secondary Treatment of Localized Prostate Cancer	2004	Hongyan Wu Leon Sun Judd W. Moul HONGYU WU David G. McLeod Christopher L. Amling Raymond Lance Leo Kusuda Timothy F. Donahue John Foley	1
+	A Peer Review Intervention for Monitoring and Evaluating sites (PRIME) that improved randomized controlled trial conduct and performance	2011	J. Athene Lane Julia Wade Liz Down Susan Bonnington Peter Holding Teresa Lennon Amanda Jones C. Elizabeth Salter David E. Neal Freddie C. Hamdy	1
+ PDF Chat	Misclassification of outcome in case–control studies: Methods for sensitivity analysis	2014	Rebecca Gilbert Richard M. Martin Jenny Donovan J. Athene Lane Freddie C. Hamdy David E. Neal Chris Metcalfe	1
+	Artificial neural network model for the assessment of lymph node spread in patients with clinically localized prostate cancer	2001	Joseph T. Batuello Eduard J. Gamito E. David Crawford Misop Han Alan W. Partin David G. McLeod Colin O’Donnell	1
+ PDF Chat	Linear Mixed Models for Longitudinal Data	1997	Geert Verbeke	1
+ PDF Chat	Using fractional polynomials to model non‐linear trends in longitudinal data	2009	Jeffrey D. Long Ji Hoon Ryoo	1
+	Research staff turnover and participant adherence in the Women's Health Initiative	2003	Marie Jackson Nancy Berman Margaret Huber Linda Snetselaar Iris Granek Kathryn Boe Carole Milas Jill Spivak Rowan T. Chlebowski	1
+	The Comparability of Models for Predicting the Risk of a Positive Prostate Biopsy with Prostate-Specific Antigen Alone: A Systematic Review	2008	Fritz H. Schröder Michael W. Kattan	1
+	Application of influence diagrams to prostate intensity-modulated radiation therapy plan selection	2004	Juergen Meyer Mark H. Phillips Paul S. Cho Ira J. Kalet Jason N. Doctor	1
+ PDF Chat	Results of Conservative Management of Clinically Localized Prostate Cancer	1994	Gerald W. Chodak Ronald A. Thisted Glenn S. Gerber Jan‐Erik Johansson Jan Adolfsson G. W. Jones G. D. Chisholm Boaz Moskovitz Pinhas M. Livne John Warner	1
+ PDF Chat	Analyzing growth trajectories	2011	Ian W. McKeague Sara López‐Pintado Marc Hallin Miroslav Šiman	1
+	Systematic review and economic modelling of the relative clinical benefit and cost-effectiveness of laparoscopic surgery and robotic surgery for removal of the prostate in men with localised prostate cancer.	2012	Craig Ramsay Robert Pickard Clare Robertson Andrew Close Luke Vale Nigel Armstrong Daniel A. Barocas CG Eden Cynthia Fraser Tara Gurung	1
+	Developing systems for cost-effective auditing of clinical trials	1997	Robert M. Califf Sharon L. Karnash Lynn H. Woodlief	1
+	Expectant management as an option for men with stage T1c prostate cancer: a preliminary study	1997	James L. Mohler Bernadette T. Williams John A. Freeman James L. Mohler	1
+	Sensitivity Analysis of Misclassification: A Graphical and a Bayesian Approach	2006	Haitao Chu Zhaojie Wang Stephen R. Cole Sander Greenland	1
+	Modeling Prostate Specific Antigen Kinetics in Patients on Active Surveillance	2006	Liying Zhang Andrew Loblaw Laurence Klotz	1
+ PDF Chat	Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis	2015	Nora Pashayan Stephen W. Duffy David E. Neal Freddie C. Hamdy Jenny Donovan Richard M. Martin Patricia Harrington Sara Benlloch Ali Amin Al Olama Mitul Shah	1
+	Robust Locally Weighted Regression and Smoothing Scatterplots	1979	William S. Cleveland	1